CA-CEQUENCE-SECURITY
10.9.2019 06:02:08 CEST | Business Wire | Press release
Cequence Security, a provider of innovative application security solutions for today’s hyper-connected enterprises, today advanced its global expansion with the opening of its EMEA headquarters in Munich, Germany, and the appointments of accomplished cybersecurity executives David Curran as Vice President, EMEA, and James Sherlow as Director of Solutions Engineering. The Cequence Application Security Platform (ASP), which consolidates multiple security functions and breakthrough innovations to protect web, mobile, and API-based applications, will be showcased at three important events:
- OWASP Global AppSec Conference in Amsterdam, September 26-27, 2019, where Cequence Chief Product Officer and Co-Founder Ameya Talwalkar will be featured as a speaker.
- ISMG Cybersecurity Summit in London, October 22, 2019, where Ameya Talwalkar will also be featured as a speaker.
- Aviation ISAC Summit in Barcelona, Spain, the global event for aviation cybersecurity, October 30-November 1, 2019, where Cequence Chief Technology Officer and Co-Founder Shreyans Mehta will be featured as a speaker.
The award-winning Cequence platform, designed to support today’s cloud-native, container-based applications, was most recently chosen over numerous contenders as “Startup of the Year” in security software by Network Products Guide. The company and platform have amassed seven recognitions and awards from peers, customers, and analysts since the platform’s launch in November 2018.
Global leaders in the retail, financial, consumer services, and social media sectors rely on Cequence ASP and its integrated modules to protect their web, mobile, and API-based application tier with unprecedented effectiveness. The CQ botDefense Module thwarts malicious bot attacks by using the patented CQAI analytics engine to detect and defend against automated attacks that appear to be legitimate. The CQ appFirewall module similarly employs CQAI to provide non-stop security, even with continuous application updates and modifications to production apps at scale by DevOps teams. It prevents attacks targeting web, mobile, and API-based applications, and helps eliminate unwanted application traffic on enterprise networks.
“Hyperconnected organizations across the EMEA region are leading today’s digital economy, and their Internet-facing applications and APIs are increasingly the targets of advanced semantic and syntactic attacks,” said David Curran, Cequence Vice President, EMEA. “Cequence ASP provides unprecedented protection against business logic abuse such as Account Takeover, Fake Accounts, Content Scraping, Denial of Inventory, Application-level DDoS, API Abuse, Gift Card Fraud, Click Fraud, and Aggregator Abuse. It’s game-changing technology and I’m honored by the opportunity to help strengthen the security posture of these organizations.”
Additional Resources:
David Curran, Vice President, EMEA – bio
James Sherlow, Director of Solutions Engineering, EMEA – bio
Cequence Security
About Cequence Security
Cequence Security is a venture-backed cybersecurity software company founded in 2015 and based in Sunnyvale, CA. Its mission is to transform application security by consolidating multiple innovative security functions within an open, AI-powered software platform that protects customers web, mobile, and API-based applications – and supports today’s cloud-native, container-based application architectures. The company is led by industry veterans that previously held leadership positions at Palo Alto Networks and Symantec. Customers include F500 organizations across multiple vertical markets, and the solution has earned multiple industry accolades, including 2018 Gartner Cool Vendor. Learn more at www.cequence.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909006012/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom